Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

Lexeo Therapeutics (NASDAQ:LXEO - Free Report) had its price target decreased by Chardan Capital from $22.00 to $20.00 in a report published on Tuesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock. Chardan Capital also issued estimates for Lexeo Therapeutics' FY2025 earnings at ($2.98) EPS.

A number of other brokerages also recently weighed in on LXEO. Royal Bank of Canada lowered their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. HC Wainwright reissued a "buy" rating and set a $23.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, April 8th. Finally, Leerink Partners cut their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a report on Monday, March 24th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $20.20.

Lexeo Therapeutics Stock Up 20.0%

Shares of Lexeo Therapeutics stock traded up $0.54 on Tuesday, reaching $3.24. The company's stock had a trading volume of 1,738,822 shares, compared to its average volume of 481,394. Lexeo Therapeutics has a 52 week low of $1.45 and a 52 week high of $19.50. The firm's fifty day simple moving average is $3.07 and its two-hundred day simple moving average is $4.94. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $107.56 million, a price-to-earnings ratio of -1.03 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.19). Equities analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC raised its holdings in Lexeo Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 50,210 shares of the company's stock worth $454,000 after purchasing an additional 31,057 shares during the period. JPMorgan Chase & Co. increased its position in Lexeo Therapeutics by 135.6% in the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company's stock worth $93,000 after buying an additional 5,915 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Lexeo Therapeutics in the fourth quarter worth about $72,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lexeo Therapeutics during the 4th quarter valued at about $46,000. Finally, Rhumbline Advisers grew its stake in shares of Lexeo Therapeutics by 19.6% during the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock valued at $166,000 after acquiring an additional 4,127 shares during the period. Hedge funds and other institutional investors own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.